Ignite Creation Date:
2024-05-06 @ 2:43 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02113735
Status:
WITHDRAWN
Last Update Posted:
2017-09-27
First Post:
2014-04-08
Brief Title:
Safety and Efficacy Study of Acthar in Subjects With ARDS
Sponsor:
Mallinckrodt
Organization:
Mallinckrodt
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel Group Safety and Efficacy Study of HP Acthar Gel Acthar in Subjects With Acute Respiratory Distress Syndrome ARDS
Status:
WITHDRAWN
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
A company decision was made not to proceed with the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being performed to evaluate the potential efficacy and safety of Acthar as a treatment for moderate-severe Acute Respiratory Distress Syndrome ARDS Approximately 210 subjects will be randomized to 1 of 6 possible treatment groups in a 323232 ratio Study medication SM will be administered via subcutaneous SC injection for 4 weeks using a blinded gradually tapering regimen and subjects will be followed for 60 days post-randomization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None